Drawing for PAINCEPTOR

USPTO serial 78731402

PAINCEPTOR

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
KING, LINDA M
Law office
TMO LAW OFFICE 116 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with PAINCEPTOR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Terrence J. McAllister

TERRENCE J MCALLISTER OHLANDT, GREELEY, RUGGIERO & PERLE LLPONE LANDMARK SQ 10TH FLSTAMFORD, CT 06901-2682UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the relief of pain; Pharmaceutical preparations for the treatment of neurological diseases and disorders, namely, Schizophrenia, learning disorders, Bipolar Disorder, Depression, Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Stroke, Addiction, Cerebral Ischemia, Neuropathy, Retinal Pigment Degeneneration, Glaucoma, Cardiac Arrhythmia, Shingles, Huntington's Chorea, Parkinson's Disease and anxiety disorders; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases of the musculoskeletal and connective tissue system, Respiratory system, Circulatory system, Gastrointestinal system, Genitourinary system and Nervous system; Pharmaceutical preparations for the treatment of diseases and disorders of the musculoskeletal and connective tissue system, namely, Arthritis, Psoriasis, Myocitis, Dermatitis, bone cancer and eczema; Pharmaceutical preparations for the treatment of diseases and disorders of the respiratory system, namely, Asthma, Bronchitis, Sinusitis, Pharyngitis, Laryngitis, Tracheitis, rhinitis, Cystic fibrosis, Respiratory Infection, Acute respiratory Distress syndrome and emphysema; Pharmaceutical preparations for the treatment of diseases and disorders of the circulatory system, namely, Vasculitis, Haematuria syndrome, Artherosclerosis, Arteritis, Phlebitis, Carditis, Coronary Heart Disease, Ischemic Heart Disease, Angina and Acute Myocardial Infarction; Pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders, namely, Irritable Bowel Syndrome, Ulcerative colitis, Crohn's Disease, Diverticulitis, Viral and Bacterial Infection, Peptic ulcer, Chronic hepatitis, Gingivitis, Periodentitis, Stomatitis, Gastritis, Gastrointestinal reflux disease and GI cancers; Pharmaceutical preparations for the treatment of the genitourinary diseases and disorders, namely, Cystitis, Polycystic kidney disease, Nephritic syndrome, Urinary Tract infection, Kidney Stones, Cystinosis, Prostatitis, Salpingitis, Endometriosis and GU cancers; Pharmaceutical preparations for the treatment of diseases and disorders of the nervous system, namely, Neuralgia, Neuropathy, Chronic cephalic pain, headache, migraine, psychogenic pain and spinal cord injuryACTIVE—
042Pharmaceutical research and development, product evaluation and drug developmentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Feb 10, 2011MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Feb 10, 2011ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 15, 2010GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jul 15, 2010GNSIINQUIRY TO SUSPENSION E-MAILED—
Jul 15, 2010CNSISUSPENSION INQUIRY WRITTEN—
Jun 30, 2010RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Dec 30, 2009RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Dec 17, 2009RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jun 17, 2009RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jun 15, 2009RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Dec 12, 2008GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 12, 2008GNSLLETTER OF SUSPENSION E-MAILED—
Dec 12, 2008CNSLSUSPENSION LETTER WRITTEN—
Nov 13, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 13, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 10, 2008ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jun 17, 2008GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jun 17, 2008GNSIINQUIRY TO SUSPENSION E-MAILED—
Jun 17, 2008CNSISUSPENSION INQUIRY WRITTEN—
May 28, 2008RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Nov 26, 2007GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 26, 2007GNSLLETTER OF SUSPENSION E-MAILED—
Nov 26, 2007CNSLSUSPENSION LETTER WRITTEN—
Oct 31, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 31, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 31, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 31, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 10, 2007GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jun 10, 2007GNSIINQUIRY TO SUSPENSION E-MAILED—
Jun 10, 2007CNSISUSPENSION INQUIRY WRITTEN—
May 26, 2007RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
May 26, 2007ALIEASSIGNED TO LIE—
Nov 21, 2006GNSLLETTER OF SUSPENSION E-MAILED—
Nov 21, 2006CNSLSUSPENSION LETTER WRITTEN—
Oct 18, 2006TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 17, 2006CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 17, 2006TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 17, 2006GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 17, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 17, 2006DOCKASSIGNED TO EXAMINER—
Oct 18, 2005NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance